2016
DOI: 10.1016/j.fertnstert.2015.11.034
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation

Abstract: Our findings suggest that treatment for infertility does not significantly increase the risk of ovarian cancer among women with a BRCA mutation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
43
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 43 publications
(44 citation statements)
references
References 18 publications
1
43
0
Order By: Relevance
“…Recent studies suggest that BRCA mutation carriers may have decreased ovarian reserve compared with women without BRCA mutations, as well as an earlier natural menopause (Finch 2013;Wang 2014). This may impact the fertility and reproductive health of BRCA mutation carriers; therefore two studies have looked at any relationship between fertility drugs and ovarian cancer in these groups of women (Gronwald 2015;Perri 2015 Cochrane Database of Systematic Reviews 2004), another included only six cohort studies (Li 2013), one four cohort studies and three case-control studies (Gadducci 2013), and one nine cohort studies calculating the risk of ovarian cancer in infertile women treated with fertility drugs (Siristatidis 2013); yet another included 10 cohort studies (Tomao 2014). The authors for two of these meta-analyses reported a significantly elevated risk of ovarian cancer in treated subfertile women when compared to the general population (Kashyap 2003;Li 2013).…”
Section: Why It Is Important To Do This Reviewmentioning
confidence: 99%
“…Recent studies suggest that BRCA mutation carriers may have decreased ovarian reserve compared with women without BRCA mutations, as well as an earlier natural menopause (Finch 2013;Wang 2014). This may impact the fertility and reproductive health of BRCA mutation carriers; therefore two studies have looked at any relationship between fertility drugs and ovarian cancer in these groups of women (Gronwald 2015;Perri 2015 Cochrane Database of Systematic Reviews 2004), another included only six cohort studies (Li 2013), one four cohort studies and three case-control studies (Gadducci 2013), and one nine cohort studies calculating the risk of ovarian cancer in infertile women treated with fertility drugs (Siristatidis 2013); yet another included 10 cohort studies (Tomao 2014). The authors for two of these meta-analyses reported a significantly elevated risk of ovarian cancer in treated subfertile women when compared to the general population (Kashyap 2003;Li 2013).…”
Section: Why It Is Important To Do This Reviewmentioning
confidence: 99%
“…Both studies are small in size but reassuring [23] [24]. One cohort study of 1,073 BRCA mutation carriers, of which 164 (15%) patients received fertility treatment, showed no associated between fertility treatment and ovarian cancer, regardless of type of fertility treatment [24].…”
Section: Ovarian Cancermentioning
confidence: 99%
“…One cohort study of 1,073 BRCA mutation carriers, of which 164 (15%) patients received fertility treatment, showed no associated between fertility treatment and ovarian cancer, regardless of type of fertility treatment [24]. Another matched case-control study of 941 pairs of BRCA mutation carriers with and without a cancer diagnosis found no significant relationship between fertility medication use and subsequent risk of ovarian cancer [23]. …”
Section: Ovarian Cancermentioning
confidence: 99%
“…In this issue of Fertility and Sterility, Gronwald et al (4) investigated the use of fertility medications or infertility treatment and the risk of ovarian cancer among women with BRCA1 or BRCA2 mutations. They used a matched case-control study design based on BRCA mutation type, age, parity, oral contraceptive use, and history of breast cancer, and they were able to enroll a total of 941 pairs in an international, multicenter trial.…”
mentioning
confidence: 99%